PMID- 29029453
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240327
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 39
DP  - 2017 Sep 12
TI  - PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry 
      and PTEN FISH in a large retrospective prostatectomy cohort.
PG  - 65566-65576
LID - 10.18632/oncotarget.19217 [doi]
AB  - PTEN deletion is an established prognostic biomarker in prostate cancer. We 
      compared PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ 
      hybridization (FISH) in the largest existing radical prostatectomy cohort with 
      clinical follow-up data. There was high concordance between IHC and FISH: 93% 
      (3098/3330) of tumors with intact PTEN IHC showed absence of PTEN gene deletion 
      and 66% (720/1087) of cases with PTEN protein loss by IHC showed PTEN gene 
      deletion by FISH. 84% (447/533) of cases with PTEN homozygous gene deletion had 
      PTEN protein loss by IHC. PTEN loss by IHC was associated with reduced PSA 
      recurrence-free survival (RFS) in multivariable models (HR=1.3; 95% CI: 
      1.16-1.47). Among cases with either PTEN deletion or absence of PTEN deletion by 
      FISH, PTEN loss by IHC was strongly associated with reduced RFS on univariable 
      analysis (p=0.0005 and p<0.0001 respectively). Among cases with intact PTEN by 
      IHC, homozygous (p=0.04) but not heterozygous (p=0.10) PTEN gene deletion was 
      weakly associated with reduced RFS. Among cases with PTEN loss by IHC, both 
      homozygous (p=0.0044) and heterozygous (p=0.0017) PTEN gene deletion were 
      associated with reduced RFS. These data support the utility of PTEN IHC and PTEN 
      FISH as complementary screening tools for PTEN loss in prostate cancer.
FAU - Lotan, Tamara L
AU  - Lotan TL
AD  - Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
AD  - Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
FAU - Heumann, Asmus
AU  - Heumann A
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Rico, Sebastian Dwertmann
AU  - Rico SD
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Hicks, Jessica
AU  - Hicks J
AD  - Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
FAU - Lecksell, Kristen
AU  - Lecksell K
AD  - Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
FAU - Koop, Christina
AU  - Koop C
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Sauter, Guido
AU  - Sauter G
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Schlomm, Thorsten
AU  - Schlomm T
AD  - Martini-Klinik Prostate Cancer Center, University Medical Center 
      Hamburg-Eppendorf, Hamburg, Germany.
AD  - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Simon, Ronald
AU  - Simon R
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20170710
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5630353
OTO - NOTNLM
OT  - PTEN
OT  - biomarker
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
OT  - prostatic carcinoma
COIS- CONFLICTS OF INTEREST TLL has received research funding from Ventana Medical 
      Systems.
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:01
PMCR- 2017/09/12
CRDT- 2017/10/15 06:00
PHST- 2017/04/04 00:00 [received]
PHST- 2017/04/27 00:00 [accepted]
PHST- 2017/10/15 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:01 [medline]
PHST- 2017/09/12 00:00 [pmc-release]
AID - 19217 [pii]
AID - 10.18632/oncotarget.19217 [doi]
PST - epublish
SO  - Oncotarget. 2017 Jul 10;8(39):65566-65576. doi: 10.18632/oncotarget.19217. 
      eCollection 2017 Sep 12.